AI assistant
aTYR PHARMA INC — Director's Dealing 2015
May 6, 2015
34337_dirs_2015-05-06_90fdc96d-c489-4245-bb67-e50ab97bc922.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2015-05-06
Reporting Person: MENDLEIN JOHN (Director, CEO and Executive Chairman)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 221916 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Series C Redeemable Convertible Preferred Stock | $ | Common Stock (170218) | Direct | ||
| Series D Redeemable Convertible Preferred Stock | $ | Common Stock (21122) | Direct | ||
| Stock Option (right to buy) | $0.72 | 2021-03-16 | Common Stock (50979) | Direct | |
| Stock Option (right to buy) | $0.72 | 2021-03-16 | Common Stock (42228) | Direct | |
| Stock Option (right to buy) | $0.88 | 2022-09-13 | Common Stock (137871) | Direct | |
| Stock Option (right to buy) | $4.06 | 2023-06-28 | Common Stock (119214) | Direct | |
| Stock Option (right to buy) | $4.06 | 2024-03-04 | Common Stock (25144) | Direct | |
| Stock Option (right to buy) | $9.15 | 2025-04-17 | Common Stock (125720) | Direct |
Footnotes
F1: 24,247 of these shares of Common Stock are subject to the Issuer's right of repurchase, which will lapse upon the completion of a firm commitment underwritten initial public offering of the Issuer's securities in which its pre-money valuation exceeds $200 million.
F2: The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Person converts into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares convert into Common Stock on a 1-for-7.95413 basis.
F3: This option is fully vested and exercisable in full.
F4: The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on March 16, 2011. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F5: The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on June 1, 2012. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F6: The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on April 19, 2013. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F7: The shares subject to this option shall vest and become exercisable in 72 equal monthly installments beginning on January 1, 2014. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.
F8: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on April 17, 2015. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.